Meno-CTRL

---

Women’s health across midlife represents a complex interplay of hormonal transition, metabolic adaptation, immune modulation, and neuropsychological change. The perimenopausal and menopausal phases are characterised not only by fluctuations in oestrogen and progesterone, but also by changes in sleep quality, mood stability, cognitive clarity, body composition, and genitourinary comfort. While these transitions are physiological, they are frequently accompanied by symptoms that affect quality of life and functional well-being, even in the absence of overt disease.

In recent years, scientific attention has increasingly turned toward the role of the gut microbiome in modulating women’s health across the menopausal transition. The gut microbiota is now recognised as an active participant in oestrogen metabolism through the so-called oestrobolome, as well as a regulator of immune tone and gut–brain signalling. Alterations in microbial composition during midlife have been associated with changes in systemic inflammation, stress responsiveness, and metabolic flexibility, all of which intersect with menopausal symptomatology.

Probyx MenoCTRL™ was developed within this evolving scientific context as an outcome-led microbiome formulation designed to support women through hormonal transition. Rather than framing menopause as a pathological condition, MenoCTRL reflects a systems-based approach that recognises hormonal change as a life stage requiring adaptive biological support. The product combines two clinically investigated probiotic complexes—SynbÆctive® Femme and SynbÆctive® KeepCalm—developed by SynBalance. This dual-component formulation is designed to address both intimate microbiome balance and stress-related emotional resilience, two domains that frequently intersect during the menopausal transition.

Hormonal transitions during perimenopause and menopause influence multiple physiological systems beyond reproductive function. Declining oestrogen levels affect gut permeability, immune regulation, lipid metabolism, and neuroendocrine signalling. These changes may contribute to increased systemic inflammation, altered stress responsiveness, and shifts in vaginal and intestinal microbiota composition. The cumulative effect is a period of heightened biological sensitivity in which small perturbations can have disproportionate effects on well-being.

The gut microbiome plays a central role in mediating these changes. Through microbial enzymes involved in oestrogen deconjugation and reabsorption, the gut microbiota influences circulating oestrogen levels and their biological availability. At the same time, gut microbial composition affects immune tone and gut–brain communication pathways that shape mood, sleep, and stress resilience. Dysbiosis during midlife may therefore amplify menopausal symptoms by disrupting these regulatory systems.

The rationale for a combined formulation such as MenoCTRL lies in addressing these interconnected pathways simultaneously. SynbÆctive® Femme is designed to support intimate microbiome balance, recognising the importance of microbial stability in vaginal and genitourinary well-being during hormonal change. SynbÆctive® KeepCalm targets gut–brain axis signalling, reflecting the role of stress, emotional regulation, and sleep disturbance in the menopausal experience.

By integrating these two probiotic complexes, MenoCTRL adopts a systems-based strategy that aligns with the multifactorial nature of menopausal adaptation. Rather than targeting isolated symptoms, the formulation seeks to support underlying biological processes that contribute to resilience during hormonal transition.

Human clinical research exploring probiotics in women’s health has expanded across several domains, including vaginal microbiome balance, genitourinary comfort, mood regulation, and stress resilience. Studies have examined the role of specific probiotic strains and combinations in supporting intimate microbiota composition, reducing symptom burden associated with microbial imbalance, and modulating stress-related psychological outcomes.

Within this literature, translational relevance depends on strain specificity and alignment with defined outcomes. Trials evaluating probiotic formulations in women’s health contexts vary widely in design, population, and endpoints, underscoring the importance of focusing on evidence generated using the same probiotic complexes incorporated into a given product.

For MenoCTRL, the most relevant evidence derives from human studies evaluating the SynbÆctive® Femme and SynbÆctive® KeepCalm blends independently. While these studies examine distinct outcome domains, together they provide a coherent clinical foundation for a combined formulation addressing both intimate microbiome balance and emotional resilience in women.

In a clinical study reported by Petricevic et al., the probiotic formulation corresponding to SynbÆctive® Femme was evaluated in postmenopausal women with altered vaginal microbiota. Primary outcomes included changes in vaginal microbial composition and markers of vaginal well-being, while secondary outcomes assessed symptom-related measures associated with genitourinary comfort. Compared with placebo or baseline, participants receiving the probiotic formulation demonstrated improvements in vaginal microbiota balance, indicating a capacity for targeted probiotic supplementation to influence intimate microbial ecosystems during postmenopause. These outcomes are relevant to MenoCTRL as they support the role of microbiome modulation in maintaining intimate comfort during hormonal transition.

In the randomized, double-blind, placebo-controlled crossover study by Messaoudi et al., the SynbÆctive® KeepCalm blend was evaluated in adults experiencing psychological stress. Primary outcomes included validated measures of stress perception and mood state, while secondary outcomes examined sleep-related and emotional parameters. Compared with placebo, participants receiving the probiotic blend exhibited improvements in stress-related mood measures and sleep quality. These findings are particularly relevant to women in perimenopausal and menopausal phases, for whom stress sensitivity and sleep disruption are common and biologically intertwined with hormonal change.

Together, these studies demonstrate that the two probiotic complexes incorporated into MenoCTRL have been independently associated with outcomes relevant to women’s health during hormonal transition. Improvements in intimate microbiome balance and stress-related emotional parameters address complementary dimensions of the menopausal experience, supporting the rationale for their combined use.

 When synthesised collectively, the clinical evidence supports a coherent interpretation of MenoCTRL’s formulation strategy. Studies evaluating SynbÆctive® Femme demonstrate that targeted probiotic supplementation can influence vaginal microbiota composition and markers of intimate well-being in postmenopausal women. Parallel evidence for SynbÆctive® KeepCalm indicates that modulation of the gut microbiome can influence stress-related mood and sleep parameters in adults.

The convergence of these findings supports a systems-based approach to menopausal support. Rather than addressing hormonal change in isolation, MenoCTRL’s formulation acknowledges the interconnected nature of microbiome balance, immune regulation, and gut–brain signalling during midlife. The observed outcomes across studies are modest in magnitude, consistent with expectations for nutritional interventions, yet directionally meaningful within a preventive and supportive framework.

Scientific restraint remains essential in interpreting these data. The available evidence does not support claims related to treatment of menopausal disease or replacement of hormonal therapies. Instead, it supports the role of microbiome-aligned strategies in contributing to resilience and quality of life during physiological transition.

Probyx MenoCTRL™ represents a scientifically coherent application of microbiome science to women’s health across hormonal transition. Its formulation integrates two clinically investigated probiotic complexes designed to support intimate microbiome balance and stress-related emotional resilience, reflecting the multifactorial nature of the menopausal experience. By aligning formulation design with human clinical evidence across complementary outcome domains, MenoCTRL embodies a systems-based, evidence-aligned approach to supporting women through midlife adaptation.

Positioned within a preventive and non-medical framework, and interpreted with appropriate scientific restraint, MenoCTRL offers a rational nutritional strategy consistent with contemporary understanding of microbiome involvement in women’s health.